Tagrisso
Tagrisso Approved for Some With Locally Advanced, Unresectable Stage III NSCLC Following Chemoradiation
The FDA has approved Tagrisso for adult patients with locally advanced, unresectable stage III NSCLC whose disease ...
SEPTEMBER 26, 2024
For Patients With EGFR-Mutated Lung Cancer, Osimertinib Trial Might Change Guidelines
In patients with unresectable EGFRm, stage III NSCLC, Tagrisso appears destined to become the new standard ...
JULY 18, 2024
Osimertinib Scores in Post-Marketing Trial for NSCLC
Overall response rate is among the best reported for first-line therapy of EGFR-mutated NSCLC.
JULY 22, 2016
Load more